In the setting of the MED12-mutant pathway, borderline and malignant PTs might stem from a pre-existing FA and progress to a malignant phenotype following the acquisition of additional genetic alterations in cancer genes, including TERT promoter mutations and TERT amplification. Here, MED12 is linked to cancer.